Mast Cell–Mesothelial Crosstalk in Peritoneal Fibrosis

Peritoneal fibrosis is a major complication of long-term peritoneal dialysis and can progressively impair membrane transport and treatment durability. The reference study by Chen and colleagues examines an underdefined component of this process: communication between mast cells and peritoneal mesothelial cells through tryptase and protease-activated receptor 2 (PAR2). Its central contribution is to connect mast-cell degranulation with downstream MAPK/NF-κB signaling in mesothelial cells, while testing Astragalus membranaceus and Salvia miltiorrhiza as a mechanism-oriented intervention. The open-access article is available in the Journal of Inflammation Research.

Study Background and Research Question

Peritoneal dialysis exposes the peritoneum to repeated chemical and mechanical stress. High-glucose dialysis fluid can promote inflammation, mesothelial injury, extracellular-matrix remodeling, and eventual fibrosis. Mast cells are positioned to sense tissue damage and release proteases, cytokines, and other mediators, but their role in dialysis-associated peritoneal fibrosis has not been fully resolved.

The study asked two linked questions. First, does high-glucose peritoneal dialysis fluid activate mast cells and increase tryptase-dependent signaling in the peritoneum? Second, can the herbal combination of Astragalus membranaceus and Salvia miltiorrhiza, abbreviated AS, reduce fibrosis by interrupting mast-cell and mesothelial-cell crosstalk? Rather than treating AS only as a broad anti-inflammatory mixture, the authors sought to identify chemical constituents, predicted molecular targets, and experimentally measurable signaling events.

Key Innovation from the Reference Study

The principal innovation is the proposed mast cell–peritoneal mesothelial cell communication model. In this framework, activated mast cells release tryptase, tryptase stimulates PAR2 on mesothelial cells, and PAR2 activation propagates MAPK and NF-κB signaling that supports a fibrotic response. This places mast-cell degranulation upstream of mesothelial signaling rather than viewing both cell types as independent contributors.

The work also uses a layered evidence strategy. UPLC-Q-TOF-MS/MS was used to characterize AS constituents; network pharmacology and docking were then used to prioritize targets; molecular dynamics simulations assessed the stability of predicted interactions; and animal and cell models tested whether those predictions corresponded to changes in degranulation, inflammatory secretion, and fibrosis-associated proteins. This combination does not prove every predicted interaction, but it provides a rational path from mixture composition to pathway-level validation.

Methods and Experimental Design Insights

In vivo, mice received daily intraperitoneal injections of 4.25% high-glucose peritoneal dialysis fluid for four weeks to induce peritoneal injury and fibrosis. Animals treated with AS were compared with model and control groups. The investigators assessed tissue changes using immunohistochemistry and immunofluorescence, while Western blotting examined PAR2/MAPK/NF-κB pathway proteins. Transcriptomics supplied a broader view of gene-expression changes associated with treatment.

For cellular validation, murine P815 mast cells were stimulated with lipopolysaccharide to generate an activated mast-cell model. Tryptase and TNF-α secretion were measured by ELISA, transcriptomic changes were profiled, and transmission electron microscopy was used to examine cellular ultrastructure and degranulation-related morphology. Human HMrSV5 peritoneal mesothelial cells were separately exposed to tryptase to model the receiving side of the crosstalk. Western blotting was then used to assess fibrosis-related signaling and pathway activation.

The chemical-analysis component identified 40 active AS constituents. Computational analysis highlighted calycosin and tanshinone IIA as candidate ligands for MAPK1 and NF-κB1. The reported docking energies ranged from −9.1 to −6.8 kcal/mol, as described in the reference study. These values indicate favorable predicted binding, but they should be interpreted as prioritization evidence rather than direct biochemical measurements of target engagement.

Protocol Parameters

• Peritoneal fibrosis model: The published model used daily intraperitoneal administration of 4.25% high-glucose peritoneal dialysis fluid for four weeks; this parameter belongs to the reference design and should not be generalized to every fibrosis model.
• Mast-cell activation: P815 cells were stimulated with LPS before analysis by transcriptomics, ELISA, and transmission electron microscopy.
• Mesothelial-cell challenge: HMrSV5 cells were exposed to tryptase to reproduce a mast-cell mediator effect and evaluate downstream fibrotic signaling.
• Mechanistic readouts: Combine mediator measurements with PAR2, MAPK, and NF-κB pathway analysis rather than relying on a single inflammatory marker.
• Workflow recommendation: For replication, include untreated, model, AS-treated, and pathway-relevant control conditions, with independent confirmation of both mast-cell activation and mesothelial-cell response.

Core Findings and Why They Matter

High-glucose dialysis fluid increased peritoneal tryptase levels by approximately 3.2-fold in the animal model. AS treatment reduced tryptase release by 71.5% after baseline correction, according to the published results. Tissue and protein analyses further indicated reduced mast-cell degranulation and suppression of PAR2/MAPK/NF-κB activation.

The P815 experiments supported the same direction of effect in vitro. AS reduced LPS-induced tryptase secretion by 71.6% and TNF-α secretion by 58.2%, based on the study’s reported measurements. These results are important because they connect a structural event—mast-cell degranulation—with soluble inflammatory output rather than inferring activation from pathway proteins alone.

The HMrSV5 experiments added a second level of validation. Exogenous tryptase induced a fibrotic response in mesothelial cells, whereas AS attenuated that response and reduced phosphorylation of MAPK/NF-κB signaling proteins. Taken together, the data support a model in which AS acts at least partly by lowering mast-cell mediator release and limiting the ability of tryptase to activate PAR2-dependent mesothelial signaling.

For researchers, the meaningful advance is mechanistic integration. The findings suggest that peritoneal fibrosis may be studied as a multicellular signaling circuit involving immune-cell secretion, receptor activation, and mesothelial remodeling. This perspective may improve assay design by pairing mast-cell degranulation endpoints with mesothelial-cell fibrosis endpoints in the same experimental framework.

Comparison with Existing Internal Articles

The internal article Recombinant Human Oncostatin M: Applied Workflows & Troubleshooting focuses on practical cytokine stimulation and troubleshooting. Its relationship to the reference study is methodological rather than evidentiary: both emphasize controlled cell-based stimulation and reproducible response measurements, but the Chen study does not use Oncostatin M and does not establish OSM involvement in peritoneal fibrosis.

Similarly, Recombinant Human Oncostatin M: Assay Workflows discusses cytokine-response assay planning in a separate biological context. It can help researchers think about dose-response design, controls, and readout selection, while the reference paper provides the disease-specific evidence for tryptase/PAR2-mediated mast cell–mesothelial signaling. These resources should therefore be treated as complementary workflow guidance, not as proof that OSM reproduces the AS mechanism.

Limitations and Transferability

Several limitations temper the study’s conclusions. The P815 line is a murine mast-cell model and may not reproduce the phenotype, mediator profile, or activation thresholds of primary human peritoneal mast cells. HMrSV5 cells are also an in vitro model and cannot capture the vascular, immune, extracellular-matrix, and dialysis-fluid interactions present in vivo.

The computational portion has similar boundaries. Docking and molecular dynamics can prioritize calycosin, tanshinone IIA, MAPK1, and NF-κB1 for testing, but direct binding assays, genetic perturbation, and target-rescue experiments would be needed to establish causality for each interaction. Because AS contains multiple constituents, the observed effect may reflect pathway convergence or constituent cooperation rather than one dominant compound.

Transferability to clinical peritoneal dialysis also remains unresolved. The mouse exposure model reproduces selected aspects of high-glucose dialysis-fluid stress, but treatment timing, dosage, pharmacokinetics, tissue distribution, and safety cannot be inferred directly from the reported experiments. Future work should validate the axis with primary cells, human peritoneal samples, and experiments that selectively inhibit or activate PAR2 while independently controlling mast-cell degranulation.

Why this cross-domain matters, maturity, and limitations

The study’s cytokine and cell-signaling framework can inform adjacent assay systems, but cross-domain interpretation must remain cautious. Oncostatin M is a pleiotropic cytokine with documented effects on fibroblast and smooth-muscle cells and on cytokine secretion, whereas the reference paper centers on mast-cell tryptase, PAR2, MAPK, and NF-κB. Thus, an OSM experiment could be useful as a parallel cytokine-response or comparator workflow, but it should not be presented as a component of the AS mechanism or as a validated treatment for peritoneal fibrosis.

Research Support Resources

For researchers extending these findings into controlled cytokine assays, Recombinant Human Oncostatin M (E.coli, Tag Free, Lyophilized) (SKU P1045) can support parallel studies involving cytokine stimulation of fibroblast proliferation, smooth muscle cell proliferation research, Kaposi's sarcoma cell growth modulation, or a cytokine release induction assay. The product information describes a 26 kDa, tag-free, lyophilized recombinant human OSM with stated purity of at least 98%, endotoxin below 0.1 ng/μg, and ED50 below 2 ng/ml in a human TF-1 proliferation assay. These specifications should be verified against the current product documentation and optimized for the selected cell system. rh-Oncostatin M is an adjacent research reagent, not a substitute for the tryptase/PAR2 controls used in the reference study, and is intended for research use only.